logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • TWi Pharmaceuticals, Inc. drugs

    FiltersReset Filters
    14 results

    • bupropion hydrochloride 

      (Bupropion Hydrochloride)
      Twi Pharmaceuticals, Inc.

    • cyclobenzaprine hydrochloride - cyclobenzaprine hydrochloride capsule, extended release

      (Cyclobenzaprine Hydrochloride)
      Twi Pharmaceuticals, Inc.

    • dexlansoprazole  delayed release - dexlansoprazole capsule, delayed release

      (Dexlansoprazole)
      Twi Pharmaceuticals, Inc.

    • dicyclomine hydrochloride

      (Dicyclomine Hydrochloride)
      TWi Pharmaceuticals, Inc.
      Usage: Dicyclomine hydrochloride is indicated for treating functional bowel syndrome and irritable bowel syndrome in patients.

    • forfivo

      (bupropion hydrochloride)
      TWi Pharmaceuticals, Inc.
      Usage: FORFIVO XL (bupropion hydrochloride extended-release) is indicated for the treatment of major depressive disorder (MDD) in adults, as defined by the DSM. Its efficacy is supported by controlled trials for both acute and maintenance treatment of MDD. Regular reevaluation of long-term use is recommended.

    • guanfacine hydrochloride - guanfacine tablet

      (Guanfacine)
      Twi Pharmaceuticals, Inc.

    • megestrol acetate

      (Megestrol Acetate)
      TWi Pharmaceuticals, Inc.
      Usage: Megestrol acetate oral suspension is indicated for treating anorexia, cachexia, or significant weight loss in AIDS patients. It should be used after identifying and addressing treatable causes of weight loss and is not intended for prophylactic use.

    • mycophenolic acid - mycophenolic acid tablet, delayed release

      (Mycophenolic Acid)
      Twi Pharmaceuticals, Inc.

    • naproxen sodium

      (Naproxen Sodium)
      TWi Pharmaceuticals, Inc.
      Usage: Naproxen Sodium Controlled-Release Tablets are indicated for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, acute gout, primary dysmenorrhea, and for alleviating mild to moderate pain.

    • nifedipine

      (Nifedipine)
      TWI Pharmaceuticals, Inc.
      Usage: Nifedipine extended-release tablets are indicated for the management of vasospastic angina, chronic stable angina, and hypertension. They help alleviate angina symptoms and lower blood pressure, reducing cardiovascular event risks like strokes and myocardial infarctions in patients experiencing inadequate control with other treatments or those who cannot tolerate them.